Glizigen; Liquorice; Glycyrrhizin;
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
甘草酸作为药物输送系统,具有多种抗癌相关药理活性,包括抵抗放疗和化疗引起的组织毒性、广谱抗癌能力和抗多药耐药(MDR)机制。可运输物质[1]。甘草酸显着提高钙水平并刺激分泌 GLP-1 的肠道 NCI-H716 细胞中 GLP-1 的产生。通过TGR5的激活,甘草酸可以增加GLP-1的分泌[2]。在37℃下,甘草酸可以在生理磷酸盐缓冲盐水(PBS)中产生稳定、透明的以纳米团簇为微观结构的低分子量水凝胶(LMWH)[4]。
|
||
---|---|---|---|
体内研究 (In Vivo) |
甘草酸升高链脲佐菌素诱导的 1 型糖尿病大鼠(STZ 治疗的大鼠)血浆 GLP-1 水平,而氨苯蝶啶足以抑制武田 G 蛋白偶联受体 5 (TGR5) 被阻断 [1]。在小鼠中,甘草酸(50 mg/kg,腹腔注射)可显着降低 TgAb、HMGB1、TNF-α、IL-6 和 IL-1β 水平 [3]。
|
||
动物实验 |
|
||
参考文献 |
[1]. Su X, et al. Glycyrrhizic acid: A promising carrier material for anticancer therapy. Biomed Pharmacother. 2017 Sep 5;95:670-678
[2]. Wang LY, et al. Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 2017 Sep 4;95:599-604. [3]. Li C, et al. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling. Thyroid. 2017 May;27(5):722-731. [4]. Xia Zhao, et al. A Simple Injectable Moldable Hydrogel Assembled from Natural Glycyrrhizic Acid with Inherent Antibacterial Activity. ACS Appl. Bio Mater. 2020, 3, 1, 648–653 |
分子式 |
C42H62O16
|
|
---|---|---|
分子量 |
822.93
|
|
CAS号 |
1405-86-3
|
|
相关CAS号 |
Ammonium glycyrrhizinate;53956-04-0;Dipotassium glycyrrhizinate;68797-35-3
|
|
SMILES |
O([C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C(=O)O[H])O1)O[H])O[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@]([H])([C@@]([H])(C(=O)O[H])O1)O[H])O[H])O[H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])C([H])(C([H])([H])C([H])([H])[C@@]3(C([H])([H])[H])[C@]4(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]5(C([H])([H])[H])C([H])([H])C([H])([H])[C@@](C(=O)O[H])(C([H])([H])[H])C([H])([H])[C@]5([H])C4=C([H])C([C@]32[H])=O)C1(C([H])([H])[H])C([H])([H])[H]
|
|
别名 |
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.2152 mL | 6.0759 mL | 12.1517 mL | |
5 mM | 0.2430 mL | 1.2152 mL | 2.4303 mL | |
10 mM | 0.1215 mL | 0.6076 mL | 1.2152 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04028869 | Completed | Drug: Glycyrrhizic acid preparation | Autoimmune Liver Disease | Beijing Ditan Hospital | March 1, 2018 | |
NCT04742660 | Completed | Drug: Ammonium Glycyrrhizinate | Postoperative Nausea | Konkuk University Medical Center | May 11, 2021 | Not Applicable |
NCT05895773 | Completed | Drug: Povidone-Iodine Drug: Saline spray |
Ventilator Associated Pneumonia | Menoufia University | June 24, 2023 | Phase 2 Phase 3 |
NCT05788705 | Not yet recruiting | Dietary Supplement: "apigenin" and "glycyrrhizin" |
Rheumatoid Arthritis | Adel A.Gomaa | July 2023 | Not Applicable |